Compare JUBILANT LIFE SCIENCES with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES VENUS REMEDIES JUBILANT LIFE SCIENCES/
VENUS REMEDIES
 
P/E (TTM) x 15.2 -1.0 - View Chart
P/BV x 1.8 0.1 2,435.3% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   VENUS REMEDIES
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
VENUS REMEDIES
Mar-18
JUBILANT LIFE SCIENCES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs898126 713.3%   
Low Rs61861 1,010.6%   
Sales per share (Unadj.) Rs572.0301.8 189.5%  
Earnings per share (Unadj.) Rs36.2-24.9 -145.7%  
Cash flow per share (Unadj.) Rs59.52.5 2,338.8%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs301.9293.3 102.9%  
Shares outstanding (eoy) m159.2812.34 1,290.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 427.6%   
Avg P/E ratio x20.9-3.8 -556.4%  
P/CF ratio (eoy) x12.736.7 34.7%  
Price / Book Value ratio x2.50.3 787.3%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m120,6941,154 10,460.7%   
No. of employees `0002.40.9 258.4%   
Total wages/salary Rs m19,260393 4,899.4%   
Avg. sales/employee Rs Th38,120.64,026.1 946.8%   
Avg. wages/employee Rs Th8,058.4425.0 1,896.2%   
Avg. net profit/employee Rs Th2,414.3-331.8 -727.7%   
INCOME DATA
Net Sales Rs m91,1083,724 2,446.4%  
Other income Rs m35723 1,588.4%   
Total revenues Rs m91,4663,747 2,441.3%   
Gross profit Rs m17,390395 4,404.8%  
Depreciation Rs m3,709338 1,096.4%   
Interest Rs m2,198354 620.4%   
Profit before tax Rs m11,840-275 -4,300.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,26832 10,341.8%   
Profit after tax Rs m5,770-307 -1,880.1%  
Gross profit margin %19.110.6 180.0%  
Effective tax rate %27.6-11.5 -240.5%   
Net profit margin %6.3-8.2 -76.9%  
BALANCE SHEET DATA
Current assets Rs m45,8482,638 1,738.2%   
Current liabilities Rs m20,8972,305 906.7%   
Net working cap to sales %27.48.9 306.2%  
Current ratio x2.21.1 191.7%  
Inventory Days Days57135 41.9%  
Debtors Days Days5146 110.0%  
Net fixed assets Rs m65,4984,871 1,344.7%   
Share capital Rs m159123 129.1%   
"Free" reserves Rs m47,9303,496 1,371.1%   
Net worth Rs m48,0893,619 1,328.8%   
Long term debt Rs m42,4291,374 3,087.1%   
Total assets Rs m114,6857,509 1,527.4%  
Interest coverage x6.40.2 2,864.3%   
Debt to equity ratio x0.90.4 232.3%  
Sales to assets ratio x0.80.5 160.2%   
Return on assets %6.90.6 1,100.6%  
Return on equity %12.0-8.5 -141.5%  
Return on capital %12.41.6 784.6%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m12,4220-   
Fx outflow Rs m17,227517 3,335.3%   
Net fx Rs m-4,805-517 930.3%   
CASH FLOW
From Operations Rs m11,215514 2,180.2%  
From Investments Rs m-10,118-123 8,219.7%  
From Financial Activity Rs m6,574-387 -1,698.3%  
Net Cashflow Rs m7,6124 181,242.9%  

Share Holding

Indian Promoters % 45.6 32.9 138.8%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 0.2 4,833.3%  
FIIs % 21.2 0.6 3,655.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 66.4 31.8%  
Shareholders   23,815 20,121 118.4%  
Pledged promoter(s) holding % 15.9 36.4 43.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 20, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS